PRINT • ONLINE • EMAIL DELIVERED • LIVE EVENT Providing broad coverage and incisive analysis of the issues, events, trends The Magazine of Pharmaceutical Business and Marketing • medadnews.com • October 2016 • Volume 35, Number 5 • $100 and strategies shaping pharmaceutical TOP 50 PHARMACEUTICAL COMPANIES business, marketing and sales returns with a robust 2017 lineup designed to meet the needs of our pharmaceutical The Magazine of Pharmaceutical Business and Marketing • medadnews.com • February 2016 • Volume 35, Number 1 • $25 inside agenda2016 specialfeature top10pipelines specialfeature By Andrew Humphreys •
[email protected] cation was supported by data from the TURQUOISE-III TOP 10 PIPELINES trial, which demonstrated 100 percent sustained viro- Top 10 Pipelines logic response at 12 weeks AbbVie post-treatment (SVR12) in this patient population. Amgen The pharma industry’s R&D concentration has been shifting towards specialty In early December 2015, AstraZeneca AbbVie announced that FDA therapy areas as research and development returns decline for some leaders. accepted the company’s NDA Biogen for a once-daily, fixed-dosed Gilead ith the average cost of getting a novel medi- overall response rate as monotherapy treatment, including pa- version of Viekira Pak to treat By Joshua Slatko •
[email protected] cine to the marketplace at nearly $2.5 billion, tients that achieved complete remission. GT1 HCV. The proposed dos- Merck it is more crucial than ever for drug compa- Three FDA Breakthrough Therapy Designations have been ing for the fixed-dose form is Novartis W nies to succeed in their R&D efforts. However, granted by FDA for venetoclax. The first designation was re- three oral tablets, taken once according to a recent study generated by De- ceived in early 2015 for treating patients with R/R CLL with per day with a meal, with or Roche loitte in collaboration with the research and consulting firm chromosome 17p deletion.